Coherus Oncology (CHRS) Stock Analysis & Winston Score

Coherus BioSciences, now operating as Coherus Oncology, is a biotechnology company focused on developing and selling cancer treatments. It originally built its business around biosimilars — cheaper versions of expensive biologic drugs — including products like Udenyca, a biosimilar to Neulasta used to help cancer patients fight infections during chemotherapy. The company has shifted its strategy toward immuno-oncology, acquiring the PD-L1 inhibitor LOQTORZI (toripalimab) for certain head and neck cancers. Coherus makes money by selling its approved drugs to hospitals, clinics, and specialty pharmacies, primarily in the United States. It is a small-cap biotech company with a market cap around $200 million, and its deeply negative operating margins reflect heavy spending on its oncology pipeline relative to current revenue. The company's key growth driver is expanding LOQTORZI's use into additional cancer types, but the main risk is whether sales can scale fast enough to reach profitability before the company needs additional capital.